
浏览全部资源
扫码关注微信
1.广西中医药大学 研究生学院,南宁 530200
2.广西中医药大学 第一附属医院,南宁 530200
蒋锐沅,在读硕士,住院医师,从事中医药防治恶性肿瘤研究,E-mail:745183530@qq.com
荣震,硕士,主任医师,广西名中医,从事中医药防治恶性肿瘤研究,Tel:0771-5362531,E-mail:rongzhenw@163.com
网络出版日期:2020-07-06,
纸质出版日期:2020-09-05
移动端阅览
蒋锐沅,莫春梅,满婷婷等.西黄丸对炎症微环境下肺癌A549荷瘤小鼠NLRP3炎症小体及其产物和肿瘤增殖的影响[J].中国实验方剂学杂志,2020,26(17):20-28.
JIANG Rui-yuan,MO Chun-mei,MAN Ting-ting,et al.Effect of Xihuangwan on NLRP3 Inflammatory Bodies and Their Products and Tumor Proliferation of Lung Cancer A549 Bearing Nude Mice in Inflammatory Microenvironment[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(17):20-28.
蒋锐沅,莫春梅,满婷婷等.西黄丸对炎症微环境下肺癌A549荷瘤小鼠NLRP3炎症小体及其产物和肿瘤增殖的影响[J].中国实验方剂学杂志,2020,26(17):20-28. DOI: 10.13422/j.cnki.syfjx.20201722.
JIANG Rui-yuan,MO Chun-mei,MAN Ting-ting,et al.Effect of Xihuangwan on NLRP3 Inflammatory Bodies and Their Products and Tumor Proliferation of Lung Cancer A549 Bearing Nude Mice in Inflammatory Microenvironment[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(17):20-28. DOI: 10.13422/j.cnki.syfjx.20201722.
目的
2
研究并探讨西黄丸对炎症微环境下的肺癌A549荷瘤小鼠的抑瘤作用,并探讨西黄丸对肺癌A549荷瘤小鼠的血清及肿瘤组织中的核苷酸寡聚化结构域样受体蛋白3(NLRP3)炎症小体及其产物表达的影响作用。
方法
2
采用肺癌A549荷瘤小鼠模型,肺癌A549细胞采用培养基中加入脂多糖(LPS)+三磷酸腺苷(ATP)的办法造炎症微环境下的肺癌A549细胞模型。造模成功后随机分为空白组(等体积生理盐水),MCC950组(MCC950溶液,0.79 g·kg
-1
),西黄丸低、中、高剂量组(0.39,0.78,1.95 g·kg
-1
),采用口服给药的方式进行,每天给药1次,连续给药21 d,处死小鼠并剥离肿瘤组织测量肿瘤体积及质量,免疫组织化学法检测肿瘤组织NLRP3表达,蛋白免疫印迹法(Western blot)检测丙二醛(MDA),白细胞介素-1
β
(IL-1
β
),白细胞介素-18(IL-18),NLRP3炎性小体蛋白表达,眼底静脉取血以酶联免疫吸附试验(ELISA)检测血清IL-1
β
,IL-18,MDA表达水平。
结果
2
与空白组比较,MCC950组,西黄丸低、中、高剂量组的抑瘤率分别为39.21%,31.72%,42.24%,55.68%;ELISA检测发现,西黄丸高剂量组能明显下调小鼠血清中的MDA,IL-1
β
,IL-18表达水平(
P
<
0.05);Western blot结果显示,与空白组比较,西黄丸高剂量组能够有效降低小鼠肿瘤组织中的MDA,IL-1
β
,IL-18,NLRP3的蛋白表达水平(
P
<
0.05);免疫组织化学法结果显示,与空白组比较,MCC950组与西黄丸各剂量组均能降低小鼠肿瘤组织中的NLRP3炎症小体表达阳性率(
P
<
0.05),且MCC950组和高剂量西黄丸组抑制效果最好(
P
<
0.05)。
结论
2
西黄丸可以抑制荷肺癌A549细胞小鼠的肿瘤组织生长,其机制可能是通过抑NLRP3炎症小体及IL-1
β
,IL-18,MDA的表达水平,进而抑制肿瘤细胞的炎症微环境达到抑制肿瘤细胞生长的结果。
Objective
2
To study the antitumor effect of Xihuangwan on A549 lung cancer nude mice in inflammatory microenvironment
and explore the effect of Xihuangwan on the expressions of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammatory bodies and their products in serum and tumor tissue of A549 lung cancer nude mice.
Method
2
The lung cancer A549 cell model was established in nude mice with lung cancer
and the lung cancer A549 cell model was established in inflammatory microenvironment by adding lipopolysaccharide (LPS) + adenosine triphosphate (ATP) to the culture medium. After modeling
the rats were randomly divided into blank group (equal volume of normal saline)
positive drug control group (MCC950 solution
0.79 g·kg
-1
)
and low
medium
high-dose Xihuangwan groups (0.39
0.78
1.95 g·kg
-1
). The rats were administered orally once a day for 21 days
and then sacrificed. The tumor tissues were stripped to measure the tumor body. The expressions of NLRP3
malondialdehyde(MDA)
interleukin (IL)-1
β
IL-18 and NLRP3 were detected by Western blot
and the levels of IL-1
β
IL-18 and MDA were detected by enzyme linked immunosorbent assay(ELISA).
Result
2
Compared with the blank group
the tumor inhibition rates in the positive drug control group and the low
medium and high dose Xihuangwan group were 39.21%
31.72%
42.24% and 55.68%. ELISA showed that the high-dose Xihuangwan group could significantly reduce the expressions of MDA
IL-1
β
and IL-18 in the serum of nude mice (
P
<
0.05). Western blot showed that the high-dose Xihuangwan group could effectively reduce the protein expressions of MDA
IL-1
β
IL-18 and NLRP3 in tumor of nude mice (
P
<
0.05)
the results of immunohistochemistry showed that the expression rate of NLRP3 in the tumor tissues of nude mice was reduced in the positive drug group and each dose of Xihuangwan group (
P
<
0.05).
Conclusion
2
Xihuangwan can inhibit the growth of tumor tissue of A549 cells bearing lung cancer in nude mice. The mechanism may be that it can inhibit the growth of tumor cells by inhibiting the expression of NLRP3 inflammatory bodies
IL-1
β
IL-18
MDA tables
and then inhibiting the inflammatory microenvironment of tumor cells.
SIEGEL R , NAISHADHAM D , JEMAL A . Cancer Statistics [J]. CA Cancer J , 2013 , 63 ( 1 ): 11 - 30 .
WANG J , ZOU Z H , XIA H L , et al . Strebgths and weaknesses of immunothrapy for advanced non-small cell lung cancer:a Meta-analysis of 12 randomized controlled trails [J]. PLoS One , 2012 , 7 ( 3 ): e32695 .
HANAHAN D , WEINBERG R A . Hallmarks of cancer: the next generation [J]. Cell , 2011 , 144 ( 5 ): 646 - 674 .
KOLB R , LIU G H , JANOWSKI A M , et al . Inflammasomes in cancer: a double-edged sword [J]. Protein Cell , 2014 , 5 ( 1 ): 12 - 20 .
ALLEN I C , TEKIPPE E M , WOODFORD R M T , et al . The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer [J]. J Exp Med , 2010 , 207 ( 5 ): 1045 - 1056 .
TU S , BHAGAT G , CUI G , et al . Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid derived suppressor cells in mice [J]. Cancer Cell , 2008 , 14 ( 5 ): 408 - 419 .
LAMKANFI M , MALIREDDI R K , KANNEGANTI T D , et al . Fungal zymosan and mannan activate the cryopyrin inflammasome [J]. J Biol Chem , 2009 , 284 ( 31 ): 20574 - 20581 .
马杰 , 杨伟 , 关硕 , 等 . 西黄丸乙酸乙酯提取物抗肿瘤活性研究 [J]. 医药导报 , 2014 , 33 ( 3 ): 303 - 306 .
王留晏 , 李皓帆 , 俎青 , 等 . 西黄丸配合CHOP化疗方案治疗非霍奇金淋巴瘤60例 [J]. 山东中医药大学学报 , 2012 , 36 ( 4 ): 313 - 315 .
金沈锐 , 祝彼得 , 秦旭华 , 等 . 西黄丸对人肝癌细胞SMMC7721及小鼠宫颈癌细胞U14周期的影响 [J]. 时珍国医国药 , 2007 , 18 ( 11 ): 2782 - 2783 .
李新叶 , 苏亮 , 徐钰 , 等 . 西黄丸调节肿瘤微环境中Treg细胞PI3K/Akt通路的抗肿瘤作用机制研究 [J]. 世界科学技术—中医药现代化 , 2018 , 20 ( 1 ): 49 - 54 .
许慧芹 , 张临泉 . 西黄胶囊辅助调强放疗对食管癌再程放疗的近期疗效观察 [J]. 实用肿瘤杂志 , 2018 , 33 ( 1 ): 61 - 65 .
KONG H , WANG Y , ZENG X , et al . Differential expression of inflamemasomes in lung cancer cell lines and tissues [J]. Tumour Biol , 2015 , 36 ( 10 ): 7501 - 7513 .
江一鸣 , 苏亮 , 徐钰 , 等 . 西黄丸调节MEKK1/SEK1通路抑制小鼠乳腺癌生长机制研究 [J]. 现代中药研究与实践 , 2019 , 33 ( 1 ): 24 - 29 .
杜旦锋 , 郭丽 , 盛丽娜 , 等 . 西黄丸抗肿瘤转移作用及其机制研究 [J]. 中药材 , 2018 , 41 ( 8 ): 1995 - 1998 .
LAMKANFI M , DIXIT M . Mechanisms and functions of inflammasomes [J]. Cell , 2014 , 157 ( 5 ): 1013 - 1022 .
RIDKER P M , MACFADYEN J G , THUREN T , et al . Effect of interleukin-1 β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial [J]. Lancet , 2017 , 390 ( 10105 ): 1833 - 1842 .
任瑶 , 江一鸣 , 项蓉蓉 , 等 . 西黄丸组分中药调节肿瘤微环境中Treg细胞PI3K/Akt通路的抗肿瘤作用机制研究 [J]. 药物评价研究 , 2019 , 42 ( 3 ): 437 - 443 .
胡俊霞 , 关硕 , 杨伟 , 等 . 西黄丸抗肿瘤与免疫调节作用研究进展 [J]. 医药导报 , 2013 , 32 ( 8 ): 1061 - 1063 .
何丽娟 , 靳冉 , 李晋生 , 等 . 西黄丸含药血清干预人乳腺癌细胞增殖的药效强度及其与采血时间的关系 [J]. 中医杂志 , 2019 , 60 ( 14 ): 1232 - 1236 .
许涛 , 李萍 , 曾召琼 , 等 . 犀黄丸提取液对MDA-MB-231乳腺癌细胞功能的影响 [J]. 中医学报 , 2019 , 34 ( 6 ): 1226 - 1230
邵萌 , 周太成 , 殷志新 , 等 . 西黄丸的抗肿瘤作用及临床应用研究进展 [J]. 国际药学研究杂志 , 2017 , 44 ( 6 ): 504 - 509 .
李莉芳 , 陈如山 , 刘新民 , 等 . 犀黄丸诱导人肝癌细胞凋亡及其机制的研究 [J]. 中医药学刊 , 2004 , 22 ( 1 ): 125 - 126 .
赵芳芳 . 乳香挥发油及地塞米松对IL-1β介导的兔视网膜色素上皮细胞迁移、增殖及NF- κ B信号通路的影响 [D]. 银川 : 宁夏医科大学 , 2019 .
马伟 . 麝香促进肺腺癌细胞增殖及凋亡效果的体外实验研究 [J]. 四川中医 , 2016 , 34 ( 11 ): 48 - 51 .
郭少贤 , 刘永惠 , 常靖 , 等 . 麝香酮干预血瘀证乳腺癌组织血管生成相关因子表达研究 [J]. 河北中医药学报 , 2011 , 26 ( 2 ): 40 - 41 .
SHIRAKI K , ITO T , SUFIMOTO K , et al . Different effects of bile acids,ursodeoxycholic acid and deoxycholic acid,on cell growth and cell death in human colonic adenocarcinoma cells [J]. Int J Mol Med , 2005 , 16 ( 4 ): 729 - 733 .
蔡红娇 , 汪世元 , 刘烈刚 , 等 . 体外培育牛黄耐缺氧和清除自由基作用的研究 [J]. 中药药理与临床 , 2003 , 19 ( 6 ): 20 - 22 .
ZHOU R , YAZDI A S , MENU P , et al . A role for mitochondria in NLRP3 inflammasome activation [J]. Nature , 2011 , 475 ( 7354 ): 122 - 122 .
朱军民 , 陈刚 , 秦俊杰 , 等 . 糖代谢异常和炎症对胃癌的影响 [J]. 兰州大学学报:医学版 , 2018 , 44 ( 1 ): 83 - 88 .
LUO Y P , JIANG L , KANG K , et al . Hemin inhibits NLRP3 inflammasome activation in sepsis-induced acute lung injury, involving heme oxygenase-1 [J]. Int Immunop Harmacol , 2014 , 20 ( 1 ): 24 - 32 .
ISAKOV E , EISMAN-SHOMER P , BENHAR M . Suppression of the pro-inflammatory NLRP3/interleukin-1 β pathway in macrophages by the thioredoxin reductase inhibitor auranofin [J]. Biochim Biophys Acta , 2014 , 1840 ( 10 ): 3153 - 3161 .
ZAKI M H , BOYD K L , VOGEL P , et al . The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis [J]. Immunity , 2010 , 32 ( 3 ): 379 - 391 .
JULIANA C , FERNANDES-ALNEMRI T , WU J , et al . Anti-inflammatory compounds parthenolide and bay 11-7082 are direct inhibitors of the inflammasome [J]. J Biol Chem , 2010 , 285 ( 13 ): 9792 - 9802 .
TAS F , TILGEN YASAEVER C , KARABULUT S , et al . Clinical significance of serum interleukin-18 (IL-18) levels in patients with gastric cancer [J]. Biomed Pharmacother , 2015 , 70 ( 13 ): 19 - 23 .
CHOW M T , SCENEAY J , PAGET C , et al . NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases [J]. Cancer Res , 2012 , 72 ( 22 ): 5721 - 5732 .
OKAMOTO M , LIU W , LUO Y , et al . Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta [J]. J Biol Chem , 2010 , 285 ( 9 ): 6477 - 6488 .
姜华 , 闫宜青 , 江维 , 等 . NLRP3炎症小体活化、调控机制及相关疾病机制 [J]. 中国科学:生命科学 , 2017 , 47 ( 1 ): 125 - 131 .
0
浏览量
17
下载量
5
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621